Meiqi Ren

Dr. Meiqi Ren


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2025 in Cancer Biology & Therapy
Verified
Journal Article
Open access
MRMeiqi Ren
Meiqi Ren
ZAZhichao(Eric) Ai
Zhichao(Eric) Ai
YZYan Zhang
Yan Zhang
LSLinghong Shi
Linghong Shi
YLYafei Liu
Yafei Liu
ZYZhipeng Yan
Zhipeng Yan
The cancer-immunity cycle is regulated by a series of stimulatory and inhibitory factors. The stimulator of interferon genes (STING) pathway, a key stimulator of type I interferon production, connects innate and adaptive immunity to promote antitumor responses. Using a syngeneic pancreatic tumor model, we characterized the single-cell landscape changes induced by STING stimulation. Our findings revealed that STING agonist treatment reprograms transcription across multiple cell lineages, enhances innate immune responses and activates lymphocytes, thereby promoting antitumor effects. Single-cell transcriptome sequencing identified significant increases in monocytes, neutrophils, macrophages, and CD8 T cells, indicating augmented tumor inflammation. Differential gene expression analysis highlighted upregulated genes related to immune cell effector mechanisms and antigen presentation. Functional assays confirmed the enhanced tumor killing effects induced by STING activation. These results underscore the potential of STING agonists in reprogramming the tumor microenvironment to potentiate antitumor immunity, although clinical translation remains challenging owing to pharmacokinetic limitations and potential systemic toxicity. Further research is needed to optimize STING agonist delivery and dosage for effective cancer immunotherapy.

21 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
GGGlaser Glaser
Glaser Glaser
MRMeiqi Ren
Meiqi Ren
SSSandrine Sander
Sandrine Sander
RSReiner Siebert
Reiner Siebert
Background/Objectives: Burkitt lymphoma (BL) is an aggressive germinal center B-cell (gcBC) malignancy driven by MYC deregulation and cooperating molecular alterations. A mouse model combining constitutive MYC and PI3K activity in gcBC closely recapitulates key features of human BL, but its epigenetic similarity to the human disease has not been investigated in detail. Here, we compared genome-wide DNA methylation patterns between human sporadic EBV-negative BL and this murine model. Methods: DNA methylation profiles of 37 human BL samples and 20 gcBC controls were compared with those of 8 murine tumors from the MYC/PI3K driven mouse model and 11 murine gcBC controls using Illumina methylation arrays. Differentially methylated CpGs were identified using linear modeling, and chromatin-state enrichment, cross-species gene overlap, protein interaction, and pathway enrichment analyses were performed. Results: BL showed global DNA hypomethylation in both species and distinct methylation profiles from gcBCs. CpGs hypomethylated in BL were enriched at enhancers, whereas hypermethylated CpGs were strongly enriched at poised promoters. We identified 695 genes with shared hypermethylation and 512 with shared hypomethylation between human and murine BL. Restricting the analysis to regulatory regions identified 86 genes consistently hypomethylated in both species. These genes were significantly enriched for regulation of intracellular signal transduction and sphingolipid signaling. Included are regulators of GTPase and kinase signaling, such as GNA13, RASA3, RASAL1, SPRED2, PIK3R2, PRKCA, PRKCE, and FYN. The conserved set also contained genes with established roles in germinal center B-cell biology, including FOXO1, BACH2, and NR3C1. Conclusions: Human and murine BL share conserved regulatory DNA methylation features, supporting the MYC/PI3K mouse model as a system to study epigenetic mechanisms of BL.